Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

134 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A simple risk chart for initial risk assessment of 30-day mortality in patients with cardiogenic shock from ST-elevation myocardial infarction.
Cheng JM, Helming AM, van Vark LC, Kardys I, Den Uil CA, Jewbali LS, van Geuns RJ, Zijlstra F, van Domburg RT, Boersma E, Akkerhuis KM. Cheng JM, et al. Among authors: akkerhuis km. Eur Heart J Acute Cardiovasc Care. 2016 Apr;5(2):101-7. doi: 10.1177/2048872615568966. Epub 2015 Jan 14. Eur Heart J Acute Cardiovasc Care. 2016. PMID: 25589634
Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation. Results from an international trial of 9461 patients. The PURSUIT Investigators.
Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, Akkerhuis KM, Harrington RA, Deckers JW, Armstrong PW, Lincoff AM, Califf RM, Topol EJ, Simoons ML. Boersma E, et al. Among authors: akkerhuis km. Circulation. 2000 Jun 6;101(22):2557-67. doi: 10.1161/01.cir.101.22.2557. Circulation. 2000. PMID: 10840005 Clinical Trial.
Safety and preliminary efficacy of one month glycoprotein IIb/IIIa inhibition with lefradafiban in patients with acute coronary syndromes without ST-elevation; a phase II study.
Akkerhuis KM, Neuhaus KL, Wilcox RG, Vahanian A, Boland JL, Hoffmann J, Baardman T, Nehmiz G, Roth U, Klootwijk AP, Deckers JW, Simoons ML; Fibrinogen Receptor Occupancy Study (FROST) Investigators. Akkerhuis KM, et al. Eur Heart J. 2000 Dec;21(24):2042-55. doi: 10.1053/euhj.2000.2309. Eur Heart J. 2000. PMID: 11102255 Clinical Trial.
Patients with acute coronary syndromes without persistent ST elevation undergoing percutaneous coronary intervention benefit most from early intervention with protection by a glycoprotein IIb/IIIa receptor blocker.
Ronner E, Boersma E, Akkerhuis KM, Harrington RA, Lincoff AM, Deckers JW, Karsch K, Kleiman NS, Vahanian A, Topol EJ, Califf RM, Simoons ML. Ronner E, et al. Among authors: akkerhuis km. Eur Heart J. 2002 Feb;23(3):239-46. doi: 10.1053/euhj.2001.2736. Eur Heart J. 2002. PMID: 11792139 Clinical Trial.
Creatine kinase-MB elevation after percutaneous coronary intervention predicts adverse outcomes in patients with acute coronary syndromes.
Roe MT, Mahaffey KW, Kilaru R, Alexander JH, Akkerhuis KM, Simoons ML, Harrington RA, Tardiff BE, Granger CB, Ohman EM, Moliterno DJ, Lincoff AM, Armstrong PW, Van de Werf F, Califf RM, Topol EJ. Roe MT, et al. Among authors: akkerhuis km. Eur Heart J. 2004 Feb;25(4):313-21. doi: 10.1016/j.ehj.2003.12.009. Eur Heart J. 2004. PMID: 14984920 Free article. Clinical Trial.
134 results